ArticleCancers2022

Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial.

Galam Leem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.